2013

Bis S, Tsao H. Melanoma genetics: the other side. Clin Dermatol. 2013 Mar;31(2):148-55.

Chen ST, Geller AC, Tsao H. Update on the Epidemiology of Melanoma. Curr Dermatol Rep. 2013 Mar 1;2(1):24-34. PMCID: PMC3619431 [Available on 2014/3/1]

Chen YE, Tsao H. The skin microbiome: Current perspectives and future challenges. J Am Acad Dermatol. 2013 Jul;69(1):143-55. PMCID: PMC3686918 [Available on 2014/7/1]

Hung T, Piris A, Lobo A, Mihm MC Jr, Sober AJ, Tsao H, Tanabe KK, Duncan LM. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. Hum Pathol. 2013 Jan;44(1):87-94.

Ji Z, Kumar R, Taylor M, Rajadurai A, Marzuka-Alcalá A, Chen YE, Njauw CN, Flaherty K, Jönsson G, Tsao H. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res. 2013 Aug 15;19(16):4383-91. PMCID: PMC3777641 [Available on 2014/8/15]

Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricalà C, Dalle S, Duval-Modeste AB, Ghiorzo P, Grammatico P, Harland M, Hayward NK, Hu HH, Jouary T, Martin-Denavit T, Ozola A, Palmer JM, Pastorino L, Pjanova D, Soufir N, Steine SJ, Stratigos AJ, Thomas L, Tinat J, Tsao H, Veinalde R, Tucker MA, Bressac-de Paillerets B, Newton-Bishop JA, Goldstein AM, Akslen LA, Molven A. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet. 2013 Apr;50(4):264-70. PMCID:PMC3607098

Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant melanoma. Mol Cancer Ther. 2013 Jul;12(7):1171-9.

2012

Harbst K, Staaf J, Lauss M, Karlsson A, Masback A, Johansson I, Bendahl PO, Vallon-Christersson J, Torngren T, Ekedahl H, Geisler J, Hoglund M, Ringner M, Lundgren L, Jirstrom K, Olsson H, Ingvar C, Borg A, Tsao H, Jonsson GB. Molecular Profiling Reveals Low- And High-Grade Forms of Primary Melanoma. Clin Cancer Res. 2012 Aug 1;18(15):4026-36. PMCID:PMC3467105[Available on 2013/8/1]

Hawryluk EB, Sober AJ, Piris A, Nazarian RM, Hoang MP, Tsao H, Mihm MC Jr, Duncan LM. Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. J Am Acad Dermatol. 2012 Oct;67(4):727-35.

Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends Mol Med. 2012 Jan;18(1):27-35.

Ji Z, Njauw CN, Taylor M, Neel V, Flaherty KT, Tsao H. p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition. J Invest Dermatol. 2012 Feb;132(2):356-64.

Lobo AZ, Tanabe KK, Luo S, Muzikansky A, Sober AJ, Tsao H, Cosimi AB, Duncan LM. The distribution of microscopic melanoma metastases in sentinel lymph nodes: implications for pathology protocols. Am J Surg Pathol. 2012 Dec;36(12):1841-8.

Nardi V, Song YC, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan A, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012 Mar 1;18(5):1227-36.

Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: New Insights and New Therapies. J Invest Dermatol. 2012 Mar;132(3 Pt 2):854-63.

Nikolaou V, Stratigos AJ, Tsao H. Hereditary nonmelanoma skin cancer. Semin Cutan Med Surg. 2012 Dec;31(4):204-10.

Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, Deangelis MM, Gragoudas E, Duncan LM, Tsao H. Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families. PLoS One. 2012;7(4):e35295. PMCID: PMC3335872

Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012 Jun 1;26(11):1131-55. Review. PMCID: PMC3371404

Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H. EphA2 is a critical oncogene in melanoma. Oncogene. 2011 Dec 15;30(50):4921-9. PMCID: PMC3175290

2011

Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, Tsao H, Barbosa VH, Chuang TY, Duvic M, Ho VC, Sober AJ, Beutner KR, Bhushan R, Smith Begolka W; American Academy of Dermatology. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol. 2011 Nov;65(5):1032-47.

Chatzinasiou F, Lill CM, Kypreou K, Stefanaki I, Nicolaou V, Spyrou G, Evangelou E, Roehr JT, Kodela E, Katsambas A, Tsao H, Ioannidis JP, Bertram L, Stratigos AJ. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst. 2011 Aug 17;103(16):1227-35. Review.

Enzler T, Sano Y, Choo MK, Cottam HB, Karin M, Tsao H, Park JM. Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discov. 2011 Nov;1(6):496-507. PMCID:PMC3290412

Lang JM, Shennan M, Njauw JC, Luo S, Bishop JN, Harland M, Hayward NK, Tucker MA, Goldstein AM, Landi MT, Puig S, Gruis NA, Bergman W, Bianchi-Scarra G, Ghiorzo P, Hogg D, Tsao H. A Novel Flexible Multiplex Bead-based Assay for Detecting Germline CDKN2A and CDK4 Variants in Melanoma-Prone Kindreds. J Invest Dermatol. 2011 Feb;131(2):480-6. PMCID: PMC3045700

Lipworth AD, Park JM, Trefrey BL, Rubin KM, Geller AC, Sober AJ, Tsao H. Urgent access to a specialty care melanoma clinic is associated with a higher rate of melanoma detection. J Am Acad Dermatol. 2011 Jun;64(6):1060-7.

Luo S, Chaplin AC, Langley RG, Njauw CN, Duncan LM, Miller RA, Tsao H. Agminated Segmental Nevi Demonstrating Intranevic Concordance of BRAF Status. J Invest Dermatol. 2011 Mar;131(3):788-90. PMCID: PMC3173815

Luo S, Sepehr A, Tsao H. Spitz nevi and other Spitzoid lesions part I. Natural history and management. J Am Acad Dermatol. 2011 Dec;65(6):1073-84. PMCID:PMC3217183

Luo S, Sepehr A, Tsao H. Spitz nevi and other Spitzoid lesions part II. Background and diagnoses. J Am Acad Dermatol. 2011 Dec;65(6):1087-92. PMCID:PMC3217195

Sepehr A, Chao E, Trefrey B, Blackford A, Duncan LM, Flotte TJ, Sober A, Mihm MC Jr, Tsao H. Long-term outcome of Spitz-type melanocytic tumors. Arch Dermatol. 2011 Oct;147(10):1173-9.

Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H. Epha2 is a Critical Oncogene in Melanoma. Oncogene. 2011 December 15; 30(50): 4921–4929. PMCID: PMC3175290

Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O'Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature. 2011 Nov 13;480(7375):99-103. PMCID: PMC3266855

2010

Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 1;70(13):5213-9.

Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Newton Bishop JA, Bishop DT, Kanetsky PA, Hayward NK, Gillanders E, Elder DE, Avril MF, Azizi E, van Belle P, Bergman W, Bianchi-Scarrà G, Bressac-de Paillerets B, Calista D, Carrera C, Hansson J, Harland M, Hogg D, Höiom V, Holland EA, Ingvar C, Landi MT, Lang JM, Mackie RM, Mann GJ, Ming ME, Njauw CJ, Olsson H, Palmer J, Pastorino L, Puig S, Randerson-Moor J, Stark M, Tsao H, Tucker MA, van der Velden P, Yang XR, Gruis N; Melanoma Genetics Consortium. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst. 2010 Oct 20;102(20):1568-83.

Feramisco JD, Tsao H, Siegel DH. Genetics for the practicing dermatologist. Semin Cutan Med Surg. 2010 Jun;29(2):127-36. Review.

Ji Z, Flaherty KT, Tsao H. Molecular therapeutic approaches to melanoma. Mol Aspects Med. 2010 Apr;31(2):194-204. Epub 2010 Feb 20. Review.

Ko JM, Velez NF, Tsao H. Pathways to melanoma. Semin Cutan Med Surg. 2010 Dec;29(4):210-7.

Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarrà G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009 Oct;61(4):677.e1-14. PMCID: PMC3307795

Miller AJ, Tsao H. New Insights into Pigmentary Pathways and Skin Cancer. Br J Dermatol. 2010 Jan;162(1):22-8.

Sober AJ, Tsao H. Martin C. Mihm, Jr and the history of the Pigmented Lesion Clinic at the Massachusetts General Hospital. J Cutan Pathol. 2010 Apr;37 Suppl 1:8-11. No abstract available.

Tsao H, Tanabe KK, Lawrence DP, Piris A. Case records of the Massachusetts General Hospital. Case 30-2010. A 15-year-old boy with a recurrent skin lesion. N Engl J Med. 2010 Sep 30;363(14):1352-60. No abstract available.

Udayakumar D, Mahato B, Gabree M, Tsao H. Genetic determinants of cutaneous melanoma predisposition. Semin Cutan Med Surg. 2010 Sep;29(3):190-5.

Udayakumar D, Tsao H. Moderate- to low-risk variant alleles of cutaneous malignancies and nevi: lessons from genome-wide association studies. Genome Med. 2009; 1(10): 95. PMCID: PMC2784308

Wang W, Niendorf KB, Patel D, Blackford A, Marroni F, Sober AJ, Parmigiani G, Tsao H. Personalized Prediction of Germline CDKN2A Mutations and Cancer Risk in Hereditary Melanoma. Cancer Res. 2010 Jan 15;70(2):552-9. PMCID: PMC2947347

2009

Feramisco JD, Sadreyev RI, Murray ML, Grishin NV, Tsao H. Phenotypic and genotypic analyses of genetic skin disease through the Online Mendelian Inheritance in Man (OMIM) database. J Invest Dermatol. 2009 Nov;129(11):2628-36.

Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarrà G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009 Oct;61(4):677.e1-14. Review.

Nelson AA, Tsao H. Melanoma and genetics. Clin Dermatol 2009 Jan-Feb;27(1):46-52. Review.

Park JM, Tsao H, Tsao S. Acquired bilateral nevus of Ota-like macules (Hori nevus): etiologic and therapeutic considerations. J Am Acad Dermatol. 2009 Jul;61(1):88-93. Review.

Sadreyev RI, Feramisco JD, Tsao H, Grishin NV. Phenotypic categorization of genetic skin diseases reveals new relations between phenotypes, genes and pathways. Bioinformatics. 2009 Nov 15;25(22):2891-6. PMCID: PMC2773259

Udayakumar D, Tsao H. Melanoma genetics: an update on risk-associated genes. Hematol Oncol Clin North Am. 2009 Jun;23(3):415-29, vii. Review.

Udayakumar D, Tsao H. Moderate- to low-risk variant alleles of cutaneous malignancies and nevi: lessons from genome-wide association studies. Genome Med. 2009 Oct 27;1(10):95.

Yang G, Thieu K, Tsai KY, Piris A, Udayakumar D, Njauw CN, Ramoni MF, Tsao H. Dynamic Gene Expression Analysis Links Melanocyte Growth Arrest with Nevogenesis. Cancer Res. 2009 Dec 1;69(23):9029-37.

2008

Feramisco JD, Casey RL, Tsao H. Recent updates on genetics: teaching old dogmas new tricks. Pediatr Dermatol 2008;25(1):99-108. Review

Friedman RJ, Gutkowicz-Krusin D, Farber MJ, Warycha M, Schneider-Kels L, Papastathis N, Mihm MC Jr, Googe P, King R, Prieto VG, Kopf AW, Polsky D, Rabinovitz H, Oliviero M, Cognetta A, Rigel DS, Marghoob A, Rivers J, Johr R, Grant-Kels JM, Tsao H. The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas. Arch Dermatol 2008 Apr;144(4):476-82.

Harland M, Goldstein AM, Kukalizch K, Taylor C, Hogg D, Puig S, Badenas C, Gruis N, Ter Huurne J, Bergman W, Hayward NK, Stark M, Tsao H, Tucker MA, Landi MT, Scarra GB, Ghiorzo P, Kanetsky PA, Elder D, Mann GJ, Holland EA, Bishop DT, Newton Bishop J; members of GenoMEL, the Melanoma Genetics Consortium. A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer 2008 Jun;44(9):1269-74. PMCID: PMC2494985

Hocker TL, Singh MK, Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from thebenchside to the bedside. J Invest Dermatol 2008;128(11):2575-95.

Park JM, Tsao H, Tsao S. Combined use of intense pulsed light and Q-switched ruby laser for complex dyspigmentation among asian patients. Lasers Surg Med 2008;40(2):128-33.

Somoano B, Tsao H. Genodermatoses with cutaneous tumors and internal malignancies. Dermatol Clin 2008;26(1):69-87.

Sun BK, Tsao H. X-Chromosome inactivation and skin disease. J Invest Dermatol 2008 Dec;128(12):2753-9. Review.

Zhang G, Njauw CN, Park JM, Naruse C, Asano M, Tsao H. EphA2 is an essential mediator of UV radiation-induced apoptosis. Cancer Res 2008;68(6):1691-6.

2007

Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E,Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Cannon-Albright LA, Chaudru V,Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis N, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang JM, Leachman S, Mackie RM, Magnusson V, Mann G, Newton-Bishop J, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E, Study Group LM, Genomel MG. Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007 Feb;44(2):99-106. PMCID: PMC2598064

Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 2007 Feb 12;28(6):578-88.

Jarell AD, Lawrende D, Tsao H. The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. [Review]. Biologics: Targ Thera 2007;1(4):407-414. PMCID: PMC2721285

Lang J, Hayward N, Goldgar D, Tsao H, Hogg D, Palmer J, Stark M, Tobias ES, MacKie R. The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry. Genes Chromosomes Cancer 2007;46(3):277-87.

McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007 Dec 11;104(50):19936-41. PMCID: PMC2148401

Tsai KY, Tsao H. Primer on the human genome. J Amer Acad Derm 2007 May; 56(5):719-35.

Tsao H, Florez JC. Introduction to genetic association studies. [Editorial] JID 2007;127:2283-87.

Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122(2):337-41.

Tsao H, Tucker MA, Whitaker L, Yakobson E. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007 Feb;44(2):99-106.

Yang G, Curley D, Bosenberg MW, Tsao H. Loss of xeroderma pigmentosum C (xpc) enhances melanoma photocarcinogenesis in ink4a-arf-deficient mice. Cancer Res 2007;67(12):5649-57.

2006

Goggins W, Daniels GH, Tsao H. Elevation of thyroid cancer risk among cutaneous melanoma survivors. Int J Cancer 2006 Jan 1;118(1):185-8.

Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D,Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E; Melanoma Genetics Consortium (GenoMEL). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006 Oct 15;66(20):9818-28.

Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006;12(7 Pt 2):2301s-2307s. [Review].

Niendorf KB, Goggins W, Yang G, Tsai KY, Shennan M, Bell DW, Sober AJ, Hogg D, Tsao H. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet 2006 Jun;43(6):501-6.

Niendorf KB, Tsao H. Cutaneous melanoma: family screening and genetic testing. Dermatol Ther 2006 Jan-Feb;19(1):1-8.

Stratigos AJ, Yang G, Dimisianos R, Nicolaou V, Stefanaki I, Katsambas AD, Tsao H. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma. J Invest Dermatol 2006 Feb;126(2):399-401.

Yang G, Zhang G, Pittelkow MR, Ramoni M, Tsao H. Expression Profiling of UVB Response in Melanocytes Identifies a Set of p53-Target Genes. J Invest Dermatol 2006 Nov;126(11):2490-506.

2005

Somoano B, Niendorf KB, Tsao H. Hereditary cancer syndromes of the skin. Clin Dermatol 2005;23(1):85-106.

Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol 2005;125:1242-51.

2004

Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer 2004;111(5):792-4.

Tsai KY, Tsao H. The genetics of skin cancer. Am J Med Genet 2004;131C(1):82-92.

Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351(10):998-1012.

Tsao H, Feldman M, Fullerton JE, Sober AJ, Rosenthal D, Goggins W. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 2004;140(1):67-70.

Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122(2):337-41. PMCID: PMC2586668

Tsao H, Niendorf K. Genetic testing in hereditary melanoma. J Am Acad Dermatol 2004;51(5):803-8.

Tsao H, Sober AJ, Niendorf KB, Zembowicz A. Case 6-2004: a 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma. N Engl J Med 2004;350(9):924-32.

Yang G, Niendorf KB, Tsao H. A novel methionine-53-valine mutation of p16 in a hereditary melanoma kindred. J Invest Dermatol 2004;123(3):574-5.

2003

Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol 2003;139(12):1620-1624.

Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003; 97(3):639-643.

Tsao H, Mihm MC Jr, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and utaneous melanoma. J Am Acad Dermatol 2003; 49(5):865-872.

Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003; 139(3):282-288.

2002

Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, Tsao H, De Luca M, Catricala C, O'Toole KM. A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002; 22(14):5157-5172. PMCID: PMC139780

Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol 2002; 138(6):799-802.

2001

Goggins WB, Finkelstein DM, Tsao H. Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer 2001 Feb 15;91(4):874-80.

2000

Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 2000 Sep;136(9):1118-22.